Groupe d'Etude en Oncologie du Quebec

Titre	The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
Protocole ID	RADICAL PC
ClinicalTrials.gov ID	NCT03127631
Type(s) de cancer	Prostate
Phase	Autres
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	Montréal
Investigateur(trice) principal(e)	Dr Nawar Hanna
Coordonnateur(trice)	Audrey Lamoureux 514-252-3400 poste 6258
Statut	Actif en recrutement
Critètes d'éligibilité	A man with a diagnosis of prostate cancer that is either: new (i.e. the diagnosis was made within 1 year of the baseline visit) or treated with Androgen Deprivation Therapy for the first time within 1 month prior to the baseline visit, or to be treated with Androgen Deprivation Therapy for the first time within 1 month after the baseline visit
Critètes d'exclusion	Unwilling to provide consent, or Are <45 years of age Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they: see a cardiologist every year, or are undertaking all of the following: aspirin use, and statin use, and ACE-I use, and exercise 4 or more times per week

Groupe d'étude en oncologie du Québec